Cite
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.
MLA
Hyman, David M., et al. “Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.” JCO Precision Oncology, vol. 3, Nov. 2019, pp. 1–13. EBSCOhost, https://doi.org/10.1200/PO.19.00221.
APA
Hyman, D. M., Tran, B., Paz-Ares, L., Machiels, J.-P., Schellens, J. H., Bedard, P. L., Campone, M., Cassier, P. A., Sarantopoulos, J., Vaishampayan, U., Chugh, R., Mahipal, A., Lockhart, A. C., Sessa, C., Zander, T., Ng, M., Curigliano, G., Bendiske, J., Chen, X., & Choudhury, S. (2019). Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. JCO Precision Oncology, 3, 1–13. https://doi.org/10.1200/PO.19.00221
Chicago
Hyman, David M., Ben Tran, Luis Paz-Ares, Jean-Pascal Machiels, Jan H. Schellens, Philippe L. Bedard, Mario Campone, et al. 2019. “Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.” JCO Precision Oncology 3 (November): 1–13. doi:10.1200/PO.19.00221.